Should I buy or sell Enveric Biosciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enveric Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ENVB shares. View ENVB analyst ratings or view top-rated stocks .

What is Enveric Biosciences' stock price target for 2024?

1 Wall Street analysts have issued twelve-month price targets for Enveric Biosciences' shares. Their ENVB share price targets range from $10.00 to $10.00. On average, they anticipate the company's share price to reach $10.00 in the next year. This suggests a possible upside of 1,035.6% from the stock's current price. View analysts price targets for ENVB or view top-rated stocks among Wall Street analysts .

How have ENVB shares performed in 2024?

Enveric Biosciences' stock was trading at $1.30 on January 1st, 2024. Since then, ENVB shares have decreased by 32.3% and is now trading at $0.8806. View the best growth stocks for 2024 here .

Are investors shorting Enveric Biosciences?

Enveric Biosciences saw a increase in short interest in March. As of March 31st, there was short interest totaling 254,900 shares, an increase of 69.5% from the March 15th total of 150,400 shares. Based on an average trading volume of 4,230,000 shares, the short-interest ratio is presently 0.1 days. Currently, 4.2% of the shares of the company are sold short. View Enveric Biosciences' Short Interest .

When is Enveric Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ENVB earnings forecast .

What ETF holds Enveric Biosciences' stock?

AdvisorShares Psychedelics ETF holds 278,833 shares of ENVB stock, representing 3.43% of its portfolio.

When did Enveric Biosciences' stock split?

Shares of Enveric Biosciences reverse split on Friday, July 15th 2022. The 1-50 reverse split was announced on Friday, July 15th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Enveric Biosciences?

Shares of ENVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ENVB

Enveric Biosciences (ENVB) Stock Price, News & Analysis

→ Your Money is Not Safe (From American Alternative) (Ad)

Free ENVB Stock Alerts

$0.88

-0.06 (-6.38%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.88
▼
$0.95
50-Day Range: $0.81
▼
$1.66
52-Week Range: $0.65
▼
$6.98

Volume: 126,289 shs
Average Volume: 295,152 shs
Market Capitalization: $6.42 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Get Enveric Biosciences alerts:

Enveric Biosciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,035.6% Upside
$10.00 Price Target
Short Interest: Healthy
4.23% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.98) to ($1.02) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.61 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Enveric Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Enveric Biosciences has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.23% of the float of Enveric Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Enveric Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Enveric Biosciences has recently increased by 69.48%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Enveric Biosciences does not currently pay a dividend.
Dividend Growth
Enveric Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ENVB.

2.2

News and Social Media Coverage

News Sentiment
Enveric Biosciences has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
Search Interest
Only 8 people have searched for ENVB on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Enveric Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Enveric Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.00% of the stock of Enveric Biosciences is held by insiders.
Percentage Held by Institutions
Only 13.82% of the stock of Enveric Biosciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Enveric Biosciences are expected to grow in the coming year, from ($1.98) to ($1.02) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Enveric Biosciences is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Enveric Biosciences is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Enveric Biosciences has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto Swap Profits

Claim Your Complimentary Bitcoin Reward

Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

Secure Your Spot Now

About Enveric Biosciences Stock (NASDAQ:ENVB)

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

ENVB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ENVB Stock News Headlines

March 27, 2024 | benzinga.com

Enveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growth

March 21, 2024 | uk.investing.com

Enveric Biosciences Inc (ENVB)

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

March 19, 2024 | msn.com

Why Is Anxiety/Addiction-Focused Enveric Biosciences Stock Trading Higher Tuesday?

March 19, 2024 | msn.com

Enveric gains on out-licensing deal of new chemical entities for joint disease treatments

March 19, 2024 | finance.yahoo.com

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

March 12, 2024 | finance.yahoo.com

Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets

March 4, 2024 | msn.com

Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

February 29, 2024 | investorplace.com

Why Is Enveric Biosciences (ENVB) Stock Up 120% Today?

February 29, 2024 | markets.businessinsider.com

Enveric Signs Term Sheets To Pursue Out-licensing Of Three Classes Of Compounds

February 29, 2024 | businesswire.com

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds

February 26, 2024 | finance.yahoo.com

CORRECTION – Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

February 23, 2024 | markets.businessinsider.com

Enveric Biosciences To Sell Cannabinoid-Related Cancer Intellectual Property; Stock Up In Pre-Market

February 23, 2024 | businesswire.com

Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property

February 21, 2024 | msn.com

Enveric Biosciences Deepens Its Mental Health-Focused Pipeline With Library of Preclinical Compounds

February 21, 2024 | finance.yahoo.com

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

February 21, 2024 | businesswire.com

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

February 12, 2024 | msn.com

Psychedelic stocks gain after FDA priority review for MDMA therapy

February 10, 2024 | msn.com

Enveric Biosciences Granted Extension to Avoid Nasdaq Delisting

January 3, 2024 | finance.yahoo.com

Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series

December 28, 2023 | msn.com

Enveric stock jumps 13% on pipeline update

December 28, 2023 | marketwatch.com

Enveric Biosciences Shares Rise 7% After Selecting Lead Drug Candidate

December 28, 2023 | finance.yahoo.com

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

December 27, 2023 | finance.yahoo.com

Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373

December 20, 2023 | finance.yahoo.com

Bears are Losing Control Over Enveric Biosciences, Inc. (ENVB), Here's Why It's a 'Buy' Now

December 20, 2023 | finance.yahoo.com

Enveric Biosciences to Participate in Biotech Showcase 2024 During "J.P. Morgan Week 2024"

See More Headlines

Receive ENVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enveric Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/20/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ENVB
CUSIP: N/A
CIK: 890821
Web: jaypharma.co
Phone: (239) 302-1707
Fax: 732-243-9254
Employees: 7
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $10.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +1,035.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.11)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,290,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -349.01%
Return on Assets: -187.74%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.53
Quick Ratio: 1.53

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.71 per share
Price / Book: 1.24

Miscellaneous

Outstanding Shares: 7,290,000
Free Float: 7,075,000
Market Cap: $6.42 million
Optionable: Not Optionable
Beta: 0.85

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Joseph Edward Tucker Ph.D. (Age 56)
CEO & Director
Comp: $825.94k
Dr. Peter J. Facchini Ph.D. (Age 60)
Chief Innovation Officer
Comp: $332.38k
Mr. Kevin M. Coveney CPA (Age 60)
Chief Financial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ENVB Stock Analysis - Frequently Asked Questions

Should I buy or sell Enveric Biosciences stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enveric Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ENVB shares.
View ENVB analyst ratings or view top-rated stocks.
What is Enveric Biosciences' stock price target for 2024?: 1 Wall Street analysts have issued twelve-month price targets for Enveric Biosciences' shares. Their ENVB share price targets range from $10.00 to $10.00. On average, they anticipate the company's share price to reach $10.00 in the next year. This suggests a possible upside of 1,035.6% from the stock's current price.
View analysts price targets for ENVB or view top-rated stocks among Wall Street analysts.
How have ENVB shares performed in 2024?: Enveric Biosciences' stock was trading at $1.30 on January 1st, 2024. Since then, ENVB shares have decreased by 32.3% and is now trading at $0.8806.
View the best growth stocks for 2024 here.
Are investors shorting Enveric Biosciences?: Enveric Biosciences saw a increase in short interest in March. As of March 31st, there was short interest totaling 254,900 shares, an increase of 69.5% from the March 15th total of 150,400 shares. Based on an average trading volume of 4,230,000 shares, the short-interest ratio is presently 0.1 days. Currently, 4.2% of the shares of the company are sold short.
View Enveric Biosciences' Short Interest.

When is Enveric Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ENVB earnings forecast.
What ETF holds Enveric Biosciences' stock?: AdvisorShares Psychedelics ETF holds 278,833 shares of ENVB stock, representing 3.43% of its portfolio.
When did Enveric Biosciences' stock split?: Shares of Enveric Biosciences reverse split on Friday, July 15th 2022. The 1-50 reverse split was announced on Friday, July 15th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.
How do I buy shares of Enveric Biosciences?: Shares of ENVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ENVB) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial